1007873-79-1

Basic information

• Product Name: methyl 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylate
• Synonyms: methyl 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylate
• CAS NO: 1007873-79-1
• Molecular Weight: 251.281
• Mol File: 1007873-79-1.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: methyl 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylate(1007873-79-1)
• EPA Substance Registry System: methyl 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylate(1007873-79-1)

Safety Data

• Hazardous Substances Data: 1007873-79-1(Hazardous Substances Data)

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 160727-95-7 methyl 3-chloro-3-(4-fluorophenyl)-2-oxopropanoate 
• 62-55-5 thioacetamide 

Downstream Products

• 433283-22-8 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylic acid 

Relevant articles and documents

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially

AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to novel azetidine compounds of formula (I), wherein R1, R2, and X are as described in the description and their use as orexin receptor antagonists.